JPMorgan Asia Growth & Income (JAGI) Competitors

JPMorgan Asia Growth & Income (LON:JAGI) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.

Which has higher earnings and valuation, JAGI or BPCR?

BioPharma Credit has higher revenue and earnings than JPMorgan Asia Growth & Income. JPMorgan Asia Growth & Income is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JPMorgan Asia Growth & Income	£41.43M	6.64	£35.93M	£49.11	7.65
BioPharma Credit	£12.99B	0.08	£10.42B	£0.09	10.14

Is JAGI or BPCR a better dividend stock?

JPMorgan Asia Growth & Income pays an annual dividend of GBX 16 per share and has a dividend yield of 4.3%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 784.8%. JPMorgan Asia Growth & Income pays out 32.6% of its earnings in the form of a dividend. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Does the media prefer JAGI or BPCR?

In the previous week, BioPharma Credit had 2 more articles in the media than JPMorgan Asia Growth & Income. MarketBeat recorded 3 mentions for BioPharma Credit and 1 mentions for JPMorgan Asia Growth & Income. JPMorgan Asia Growth & Income's average media sentiment score of 1.55 beat BioPharma Credit's score of 1.42 indicating that JPMorgan Asia Growth & Income is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
JPMorgan Asia Growth & Income	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioPharma Credit	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is JAGI or BPCR more profitable?

JPMorgan Asia Growth & Income has a net margin of 86.71% compared to BioPharma Credit's net margin of 80.20%. JPMorgan Asia Growth & Income's return on equity of 12.22% beat BioPharma Credit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JPMorgan Asia Growth & Income	86.71%	12.22%	-0.23%
BioPharma Credit	80.20%	8.51%	4.98%

Do insiders and institutionals hold more shares of JAGI or BPCR?

29.9% of JPMorgan Asia Growth & Income shares are owned by institutional investors. Comparatively, 41.5% of BioPharma Credit shares are owned by institutional investors. 11.3% of JPMorgan Asia Growth & Income shares are owned by insiders. Comparatively, 6.2% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more risk and volatility, JAGI or BPCR?

JPMorgan Asia Growth & Income has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Does the MarketBeat Community favor JAGI or BPCR?

BioPharma Credit received 84 more outperform votes than JPMorgan Asia Growth & Income when rated by MarketBeat users.

Company	Underperform	Outperform
JPMorgan Asia Growth & Income	N/A	N/A
BioPharma Credit	Outperform Votes 84 64.62%	Underperform Votes 46 35.38%

Summary

JPMorgan Asia Growth & Income and BioPharma Credit tied by winning 8 of the 16 factors compared between the two stocks.